BACKGROUND: Programmed cell death, including apoptosis, mitochondria-mediated necrosis, and necroptosis, is critically involved in ischemic cardiac injury, pathological cardiac remodeling, and heart failure progression. Whereas apoptosis and mitochondria-mediated necrosis signaling is well established, the regulatory mechanisms of necroptosis and its significance in the pathogenesis of heart failure remain elusive. METHODS: We examined the role of tumor necrosis factor receptor-associated factor 2 (Traf2) in regulating myocardial necroptosis and remodeling using genetic mouse models. We also performed molecular and cellular biology studies to elucidate the mechanisms by which Traf2 regulates necroptosis signaling. RESULTS: We identified a critical role for Traf2 in myocardial survival and homeostasis by suppressing necroptosis. Cardiac-specific deletion of Traf2 in mice triggered necroptotic cardiac cell death, pathological remodeling, and heart failure. Plasma tumor necrosis factor α level was significantly elevated in Traf2-deficient mice, and genetic ablation of TNFR1 largely abrogated pathological cardiac remodeling and dysfunction associated with Traf2 deletion. Mechanistically, Traf2 critically regulates receptor-interacting proteins 1 and 3 and mixed lineage kinase domain-like protein necroptotic signaling with the adaptor protein tumor necrosis factor receptor-associated protein with death domain as an upstream regulator and transforming growth factor β-activated kinase 1 as a downstream effector. It is important to note that genetic deletion of RIP3 largely rescued the cardiac phenotype triggered by Traf2 deletion, validating a critical role of necroptosis in regulating pathological remodeling and heart failure propensity. CONCLUSIONS: These results identify an important Traf2-mediated, NFκB-independent, prosurvival pathway in the heart by suppressing necroptotic signaling, which may serve as a new therapeutic target for pathological remodeling and heart failure.
BACKGROUND: Programmed cell death, including apoptosis, mitochondria-mediated necrosis, and necroptosis, is critically involved in ischemic cardiac injury, pathological cardiac remodeling, and heart failure progression. Whereas apoptosis and mitochondria-mediated necrosis signaling is well established, the regulatory mechanisms of necroptosis and its significance in the pathogenesis of heart failure remain elusive. METHODS: We examined the role of tumor necrosis factor receptor-associated factor 2 (Traf2) in regulating myocardial necroptosis and remodeling using genetic mouse models. We also performed molecular and cellular biology studies to elucidate the mechanisms by which Traf2 regulates necroptosis signaling. RESULTS: We identified a critical role for Traf2 in myocardial survival and homeostasis by suppressing necroptosis. Cardiac-specific deletion of Traf2 in mice triggered necroptotic cardiac cell death, pathological remodeling, and heart failure. Plasma tumor necrosis factor α level was significantly elevated in Traf2-deficientmice, and genetic ablation of TNFR1 largely abrogated pathological cardiac remodeling and dysfunction associated with Traf2 deletion. Mechanistically, Traf2 critically regulates receptor-interacting proteins 1 and 3 and mixed lineage kinase domain-like protein necroptotic signaling with the adaptor protein tumor necrosis factor receptor-associated protein with death domain as an upstream regulator and transforming growth factor β-activated kinase 1 as a downstream effector. It is important to note that genetic deletion of RIP3 largely rescued the cardiac phenotype triggered by Traf2 deletion, validating a critical role of necroptosis in regulating pathological remodeling and heart failure propensity. CONCLUSIONS: These results identify an important Traf2-mediated, NFκB-independent, prosurvival pathway in the heart by suppressing necroptotic signaling, which may serve as a new therapeutic target for pathological remodeling and heart failure.
Authors: N Vanlangenakker; T Vanden Berghe; P Bogaert; B Laukens; K Zobel; K Deshayes; D Vucic; S Fulda; P Vandenabeele; M J M Bertrand Journal: Cell Death Differ Date: 2010-11-05 Impact factor: 15.828
Authors: M Andrassy; H C Volz; N Riedle; G Gitsioudis; C Seidel; D Laohachewin; A R Zankl; Z Kaya; A Bierhaus; E Giannitsis; H A Katus; G Korosoglou Journal: J Intern Med Date: 2011-03-28 Impact factor: 8.989
Authors: Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan Journal: Cell Date: 2009-06-12 Impact factor: 41.582
Authors: I Karl; M Jossberger-Werner; N Schmidt; S Horn; M Goebeler; M Leverkus; H Wajant; T Giner Journal: Cell Death Dis Date: 2014-10-09 Impact factor: 8.469
Authors: Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis Journal: Physiol Rev Date: 2019-10-01 Impact factor: 37.312
Authors: Yoav Hadas; Adam S Vincek; Elias Youssef; Magdalena M Żak; Elena Chepurko; Nishat Sultana; Mohammad Tofael Kabir Sharkar; Ningning Guo; Rinat Komargodski; Ann Anu Kurian; Keerat Kaur; Ajit Magadum; Anthony Fargnoli; Michael G Katz; Nadia Hossain; Ephraim Kenigsberg; Nicole C Dubois; Eric Schadt; Roger Hajjar; Efrat Eliyahu; Lior Zangi Journal: Circulation Date: 2020-01-29 Impact factor: 29.690
Authors: Sarah Evans; Huei-Ping Tzeng; Deborah J Veis; Scot Matkovich; Carla Weinheimer; Attila Kovacs; Philip M Barger; Douglas L Mann Journal: JCI Insight Date: 2018-02-08